CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Human-specific Proteins Uncovered by Exploring Genetic Uncharted Territory

Human-specific Proteins Uncovered by...

A Broader Perspective of Genomics

A Broader Perspective of Genomics

The Future Of Genomics In Theory-Focused Approaches

The Future Of Genomics In...

Role of Human Genomic Data in Future

Role of Human Genomic Data in Future

Essentiality of Single-cell Genomics Technology

Essentiality of Single-cell Genomics...

Tactics to Handle Genomic Data

Tactics to Handle Genomic Data

Benefits of Advanced Genomic Testing

Benefits of Advanced Genomic Testing

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Human-specific Proteins Uncovered by Exploring Genetic Uncharted Territory

Human-specific Proteins Uncovered by...

A Broader Perspective of Genomics

A Broader Perspective of Genomics

The Future Of Genomics In Theory-Focused Approaches

The Future Of Genomics In...

Role of Human Genomic Data in Future

Role of Human Genomic Data in Future

Essentiality of Single-cell Genomics Technology

Essentiality of Single-cell Genomics...

Tactics to Handle Genomic Data

Tactics to Handle Genomic Data

Benefits of Advanced Genomic Testing

Benefits of Advanced Genomic Testing

US FDA Award VICO with Therapeutics Orphan-Drug Designation for VO659

Life Sciences Review Life Sciences Review | Thursday, March 17, 2022
Tweet

VICO Therapeutics has announced that the US Food and Drug Administration's Office of Orphan Products Development (OOPD) had granted the company a patent.


FREMONT, CA: VICO Therapeutics, a biotech firm based in Leiden, the Netherlands, focuses on developing RNA modulating therapies for rare neurological disorders, announces that the US Food and Drug Administration's Office of Orphan Products Development (OOPD) had granted the company a patent. The Food and Medication Administration (FDA) has designated VO659, VICO's investigational antisense oligonucleotide (AON) therapy for the treatment of spinocerebellar ataxia (SCA), as an orphan drug. The European Commission granted VICO orphan drug classification for VO659 in SCA in February.


Rupert Sandbrink, MD PhD., Chief Medical Officer at VICO, stated: "Spinocerebellar ataxia belongs to the group of polyglutamine disorders which are debilitating and progressive diseases, leading to significant impairment of mobility and multiple other daily activities of patients suffering from these conditions. Currently, no disease modifying treatments are available for these patients. Our investigational RNA modulating therapy is designed to lower the mutant protein levels causing these neurodegenerative diseases."


"We're excited to obtain orphan-drug designation from also the FDA, following the EC grant earlier this year. This deeply underserved patient population deserves new therapies, and we look forward to advancing VO659, our therapy that holds great potential for addressing their unmet needs. It also recognizes the potential of our AON approach. This is yet another important step forward as we prepare for our first in human trials, expected to start in 2022."


Orphan Drug Designation is granted by the FDA's Office of Orphan Products Development to medicines and biologics designed for the safe and efficient treatment, diagnosis, or prevention of rare diseases/disorders that impact fewer than 200,000 persons in the United States. VICO will be eligible for various benefits due to the designation, including seven years of market exclusivity upon regulatory clearance, a waiver of FDA application fees for spinocerebellar ataxia, and tax credits for approved clinical trials.


Weekly Brief

loading
Top 10 Genomics Solutions Companies in Europe/UK – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/us-fda-award-vico-with-therapeutics-orphandrug-designation-for-vo659-nwid-449.html